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Indoleamine2,3-dioxygenase1 (Ido1) is a rate-limiting
enzyme that catalizes the degradation of tryptophan
along the kynurenine pathway. Here, we show that
Ido1 activity sustains an immunostimulatory poten-
tial through inhibition of interleukin (Il)10. In athero-
sclerosis, Ido1-dependent inhibition of Il10 trans-
lates into disease exacerbation. The resistance of
Ido1-deficient mice to enhanced immune activation
is broken in Ido1/Il10 double-deficient mice, which
show exaggerated immune responses and develop
severe spontaneous colitis. We demonstrate that
Ido1 activity is required for the regulation of Il10 and
that kynurenic acid (Kna), an Ido1-derivedmetabolite,
is responsible for reduced Il10 production through
activation of a cAMP-dependent pathway and inhibi-
tion of Erk1/2 phosphorylation. Resupplementation
of Ido1-deficient mice with Kna limits Il10 expression
and promotes atherosclerosis. In human atheroscle-
rotic lesions, increased levels of Kna are associated
with an unstable plaque phenotype, and its blood
levels predict death and recurrent myocardial infarc-
tion in patients with coronary artery disease.
INTRODUCTION
Tryptophan (Trp) catabolism by Ido1 through the kynurenine
(Kyn) pathway has first been implicated in innate host defense460 Cell Metabolism 22, 460–471, September 1, 2015 ª2015 Elsevieagainst microbial infection (Zelante et al., 2009). In 1998,
Munn, Mellor, and colleagues reported maternal T cell-induced
rejection of allogeneic fetuses in mice treated with 1-methyl-
Trp (1-MT), a pharmacologic inhibitor of Ido1 activity (Munn
et al., 1998), and proposed a role for Ido1 in the induction or
maintenance of immune tolerance. Since that report, Ido1 has
been shown to be induced in inflammatory settings mainly in
the context of interferon (Ifn) type I and toll-like receptor stimula-
tion (Yoshida et al., 1981), and has been involved in various
disease states, including autoimmune diseases, allergy, trans-
plant tolerance, chronic infection, ganulomatous diseases, and
cancer (Mellor and Munn, 2004; Munn and Mellor, 2007; Platten
et al., 2005). Mechanistically, Trp depletion activates the stress
response pathway (Munn et al., 2005), and the generation of
Kyn, an endogenous ligand of the aryl hydrocarbon receptor,
leads to important immune modulatory effects (Munn et al.,
2005; Opitz et al., 2011). Kyn catabolites may directly affect
the survival and function of T cells, inducing effector T cell
apoptosis and tipping the balance toward enhanced Treg and
reduced Th1 or Th17 responses (Platten et al., 2005; Romani
et al., 2008; Terness et al., 2002). Based on this knowledge,
Ido1 inhibitors have been developed and are now being evalu-
ated in several clinical trials with the aim to mount effector im-
mune responses in the settings of cancer or infection (Lo¨b
et al., 2009a).
A fine-tuned balance between effector and regulatory immune
responses also controls the development of atherosclerosis
(Tedgui and Mallat, 2006), an inflammatory vascular disease
responsible for the first cause of death worldwide. In this setting,
Ido1 is also seen as a potentially important regulator of the
immune response, limiting pathogenic adaptive T cell activation
(Cuffy et al., 2007; Daissormont et al., 2011; Nakajima et al.,r Inc.
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Figure 1. Ido1 Deficiency Reduces the Development of Atherosclerosis in Mice
(A) Circulating Ido activity (Kyn:Trp ratio) in Ldlr/Ido1/ compared to Ldlr/ mice.
(B) Representative photomicrographs and quantification of lesion size in aortic sinus of male Ldlr/ (n = 16) and male Ldlr/Ido1/mice (n = 13) after 8 weeks
on HFD.
(C) Expression of Ido1 in spleens of female Ldlr/mice reconstituted with either control (Ido1+/+/ Ldlr/) (n = 8) or Ido1/ (Ido1// Ldlr/) (n = 11) bone
marrow.
(D) Representative photomicrographs and quantification of lesion size in aortic sinus of Cont/ Ldlr/and Ido1// Ldlr/ mice after 6 weeks on HFD.
(E) Plasma cholesterol levels in the two groups of mice. Mean values ± SEM are shown.
(F) Representative photomicrographs and quantification of lesion size in thoracic aorta of Cont/ Ldlr/ and Ido1// Ldlr/mice after 6 weeks on HFD.
*p < 0.05, **p < 0.001, ***p < 0.0001. See also Figure S1.2011). However, those studies were based on incomplete and
probably nonselective pharmacologic inhibition of Ido activity
(Nakajima et al., 2011; Polyzos et al., 2015), or involved supple-
mentation with supraphysiologocial levels of Ido metabolites
(Polyzos et al., 2015; Zhang et al., 2012). Furthermore, those
experimental data are not in line with the intriguing positive
association reported between circulating ‘‘Ido activity’’ (Kyn-
to-Trp ratio) and cardiovascular events in stable coronary artery
disease (CAD) patients (Pedersen et al., 2011, 2015). We there-
fore aimed to address the direct role of Ido1 in the modulation
of immunoinflammatory responses and its potential impact on
the development of atherosclerosis. Our results revealed a pre-
viously unsuspected role of Ido1 in repressing the anti-inflamma-
tory cytokine Il10, which may have major implications for our
understanding of the role of Ido1 in immune tolerance or the
development of immune-mediated diseases.
RESULTS
Ido1 Deficiency Unexpectedly Reduces the
Development of Atherosclerosis
We analyzed Ido activity during the development of athero-
sclerosis as assessed by circulating Ido-derived metabolites in
atherosclerosis-prone low-density lipoprotein receptor-deficientCell Me(Ldlr/) mice put on chow versus high-fat diet (HFD) during
7 weeks. As shown in Figure S1 (available online), plasma
Kyn:Trp as well as circulating levels of kynurenic acid (Kna)
and quinolinic acid increased significantly in Ldlr/ mice on
HFD. Furthermore, levels of Kyn, Kna, and quinolinic acid were
higher in spleen extracts of Ldlr/mice on HFD. Specifically,
Ido1 expression colocalized with macrophages and smooth
muscle cells in aortic sinus of Ldlr/ mice (Figure S1). These
results highly suggest increased Ido1 activity with the develop-
ment of atherosclerosis.
To address the direct role of Ido1 in this context, we crossed
Ldlr/ mice with Ido1/ mice and generated Ldlr/Ido1/
mice and Ldlr/Ido1+/+ littermate controls. Both groups of
mice were put on HFD for 8 weeks. Plasma Kyn/Trp ratio was
markedly suppressed in Ldlr/Ido1/ mice (Figure 1A). Sur-
prisingly, Ldlr/Ido1/ mice showed significant reduction in
aortic root atherosclerosis compared with Ldlr/Ido1+/+ litter-
mates (Figure 1B), despite similar plasma cholesterol levels
(13.20 ± 0.66 g/L versus 13.98 ± 0.41 g/L, p = 0.38). Plaque
area was also significantly decreased in Ldlr/Ido1/ mice in
the thoracic aorta (data not shown).
We also reconstituted irradiated Ldlr/ mice with Ido1+/+ or
Ido1/ bone marrow (Figure 1C). After 4 weeks of recovery,
mice were put on HFD for 6 weeks. Again, mice reconstitutedtabolism 22, 460–471, September 1, 2015 ª2015 Elsevier Inc. 461
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Figure 2. Ido1 Deficiency Is Associated with Enhanced Il10 Production
(A) Expression of Ido1 and Il10 in control and Ido1-deficient BMDM before and after stimulation with LPS and Ifn-g for 24 hr.
(B) Il10 production in the supernatants of control and Ido1-deficient BMDM stimulated with LPS+Ifn-g with or without incubation with Erk1/2 inhibitor PD98059
(105 M).
(C) Il10 expression is increased in spleens of Ldlr/Ido1/ (n = 9) compared to Ldlr/ (n = 9) mice.
(D) Representative examples and quantitative analysis of flow cytometry-based intracellular staining of Il10 gated on CD11b+F4/80+ cells in the two groups of
mice (Ldlr/, n = 6; Ldlr/Ido1/, n = 6).
(E) Ido1 activity (Kyn:Trp) is increased after stimulation with Poly:IC or LPS and Ifn-g for 24 hr.
(F) Il10 production in the supernatants of control and Ido1-deficient BMDM after stimulation with LPS and Ifn-g, CpG type B, or Poly:IC for 24 hr.
(G) Il10 production in the supernatants of control and Ido1-deficient BMDM after inhibition of Ido activity with DPI (1 mM) or using a Trp-deprived medium. Mean
values ± SEM are shown. *p < 0.05, **p < 0.001, ***p < 0.0001. See also Figures S2 and S3.with Ido1/bonemarrowshowedsignificant reduction inathero-
sclerosis at the aortic root (Figure 1D) and thoracic aorta (Fig-
ure 1F), compared with mice reconstituted with Ido1+/+ bone
marrow, despite similar plasma cholesterol levels (Figure 1E).
Furthermore, Ldlr/ and Ldlr/Ido1/ mice reconstituted
with Ido1+/+ bone marrow showed similar plaque size, indicating
that Ido1 expression in non-bone-marrow-derived cells does not
contribute significantly to atherosclerosis (data not shown).
Ido1 Deficiency in Bone-Marrow-Derived Cells Is
Associated with Enhanced Il10
The findings were unexpected, given thewidely described role of
Ido1 in the downregulation of immune responses. We therefore
examined the impact of Ido1 deletion on the production of
several cytokines, such as Il10, Il12, Tnf-a, and Il6, which play
important roles in atherosclerosis development (Tedgui and
Mallat, 2006). Thus, we subjected bone-marrow-derived macro-
phages (BMDMs) to stimulation with LPS and Ifn-g (known462 Cell Metabolism 22, 460–471, September 1, 2015 ª2015 Elsevieinducers of Ido1), which led to increased Ido1 expression (Fig-
ure 2A). Interestingly, Il10 was upregulated in Ido1/ compared
with Ido1+/+ macrophages (Figures 2A and 2B), suggesting an
anti-inflammatory phenotype in the absence of Ido1. Ido1 defi-
ciency did not alter the production of the other cytokines, Il12,
Tnf-a, or Il6 (Figure S2). Inhibition of Erk1/2 phosphorylation
abolished the increase of Il10 in Ido1/ macrophages (Fig-
ure 2B), indicating the importance of this pathway in the process.
Il10 increase in the absence of Ido-1 was also observed in peri-
toneal macrophages (data not shown). Accordingly, freshly
isolated Ido1-deficient peritoneal cells from Ldlr/Ido1/
showed a significant increase of Erk1/2 phosphorylation, which
is consistent with the role of Erk1/2 in Il10 production (Saraiva
and O’Garra, 2010), and increased phosphorylation of Stat3
(Figure S2), which is consistent with enhanced downstream
Il10 signaling (Moore et al., 2001).
We also studied Flt3 ligand-induced bone-marrow-derived
dendritic cells (DCs) (mostly plasmacytoid [Gilliet et al., 2002]),r Inc.
A B
C D E
F G H
Figure 3. Kna Limits Il10 Production through
Inhibition of Erk1/2 Phosphorylation and
Increase of Intracellular cAMP
(A) Production of Il10 in the supernatants of
control and Ido1-deficient BMDM after stimulation
with LPS (for 16 hr) with or without incubation
with Erk1/2 inhibitor PD98059 (105 M) or Kna
(1 mM).
(B) Erk1/2, p38, and JNK phosphorylation in BMDM
incubated with Cont or Kna (1 mM) or Quina (1 mM)
for 24 hr, then stimulated with LPS and Ifn-g for
the last 30 min. One representative result of three
independent experiments is shown.
(C) Intracellular cAMP levels in Ido1-deficient
BMDM with or without treatment with Kna (1 mM)
after 16 hr of stimulation with LPS.
(D) Intracellular cAMP levels in Ido1+/+ and Ido1-
deficient BMDM after 16 hr of stimulation with LPS
and Ifn-g.
(E) Production of Il10 in the supernatants of Ido1-
deficient BMDM after stimulation with LPS (for
16 hr) with or without incubation with adenylate
cyclase inhibitor (10 mM).
(F) Production of Il10 in the supernatants of control
BMDM after stimulation with LPS (for 16 hr) with or
without incubation with Mrp4 inhibitor, MK571
(10 mM).
(G and H) (G) Circulating levels of Kna (G) and Il10 expression in spleen (H) after in vivo supplementation of male Ldlr/Ido1/mice with vehicle (Cont) (n = 10) or
Kna (n = 10). Mean values ± SEM are shown. *p < 0.05, **p < 0.001, ***p < 0.0001. See also Figures S4 and S5.known to express Ido1 (Mellor et al., 2004) in response to stimu-
lation with LPS and Ifn-g. Again, Ido1/ DCs showed a signifi-
cant increase of Il10 production and reduced Il12 compared to
Ido1+/+ DCs (Figure S2). We then examined cytokine production
by splenocytes and plasmacytoid DCs (pDCs) isolated from
Ldlr/ and Ldlr/Ido1/ mice at the end of 8 weeks of HFD
after ex vivo stimulation with LPS and Ifn-g. Here too, we found
a skewed cytokine profile toward increased Il10 production in
the absence of Ido1 (Figure S2). We also found increased Il10
expression in spleens (Figure 2C), and more particularly in
F4/80+CD11b+ macrophages of Ldlr/Ido1/ compared to
Ldlr/ mice (Figure 2D).
Tlr4 activation by LPS triggers both Myd88-dependent and
independent (Trif-dependent) signaling pathways. We therefore
subjected BMDM to stimulation with Poly:IC (Tlr3 agonist) or
CpG type B (Tlr9 agonist), which selectively engage Trif-depen-
dent or Myd88-dependent signaling pathways, respectively. As
shown in Figures 2E and 2F, Ido1/ macrophages displayed
higher Il10 production than their Ido1+/+ counterparts in
response to Poly:IC, which was not the case after CpG stimula-
tion despite similar induction of Ido1 (data not shown). These re-
sults suggest that Ido1 modulates a Trif-dependent signaling
pathway to limit Il10 production.
We then wanted to know whether Ido activity was required for
the observed changes in Il10 and plaque size. We treated Ldlr/
mice with L-1MT, known to inhibit Ido1 activity with a 10-fold
higher affinity than the D-isomer (Lo¨b et al., 2009b). 1-MT treat-
ment led to a significant decrease of Ido activity as assessed
by plasma Kyn/Trp ratio (Figure S3). However, contrary to what
we observed in Ldlr/Ido1/ mice, 1-MT altered neither Il10
expression nor plaque size (Figure S3). It is noteworthy that, in
contrast to Ido1 deficiency, treatment with 1-MT significantlyCell Meincreased the expression of the proinflammatory and proathero-
genic factor Il12 (Davenport and Tipping, 2003; Hauer et al.,
2005), also known to inhibit Il10 (Segal et al., 1998). To examine
whether this effect of 1-MT on Il12 production was related to the
inhibition of Ido1 activity, we treated both control and Ido1/
BMDM with 1-MT in vitro. Consistent with the in vivo data,
1-MT induced significant Il12 production in control but also in
Ido1/ BMDMs (Figure S3), which strongly argues in favor of
an off-target effect of 1-MT, independent of its inhibitory effect
on Ido1 activity (Figure S3).
To circumvent this problem, inhibition of Ido activity was
achieved by incubation of macrophages in Trp-free medium
or in the presence of diphenyleneiodonium (DPI), which inhibits
Napdh oxidase (required for Ido activity (Romani et al., 2008)).
Trp depletion or treatment with DPI markedly decreased Kyn/Trp
ratio in cell supernatants (Figure S4), and abolished the differ-
ence in Il10 production between Ido1+/+ and Ido1/ cells (Fig-
ure 2G), supporting a role for Ido1 activity in the regulation of
Il10 production.
Kna Limits Il10 Production through Inhibition of Erk1/2
Phosphorylation
We next addressed the mechanisms responsible for this Ido1-
dependent proinflammatory response. We examined the effect
of Ido1-derived metabolites on Il10 production by BMDMs.
Incubation with Kyn slightly altered cytokine production in
response to LPS and Ifn-g (Figure S4). In contrast, Kna selec-
tively reduced Il10 production in Ido1+/+ and Ido1/ BMDM
(Figures 3A and S4). This effect was also found after stimula-
tion with Poly:IC, suggesting the involvement of a Trif-depen-
dent pathway (Figure S4). To address the mechanisms respon-
sible for Kna-dependent regulation of Il10, we examined earlytabolism 22, 460–471, September 1, 2015 ª2015 Elsevier Inc. 463
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Figure 4. Kna Supplementation in
Ldlr–/–Ido1–/– Mice Increases Plaque Size
(A) Plasma cholesterol levels in the two groups of
mice. Mean values ± SEM are shown.
(B and C) Representative photomicrographs and
quantification of lesion size in aortic sinus of male
Ldlr/ Ido1/ mice supplemented with vehicle
(Cont) (n = 10) or Kna (n = 10).
(D–F) Plasma Kna levels are strongly correlated to
plaque size (D) and inversely correlated to Il10
expression in spleens (E). Il10 expression in
spleens is inversely correlated to plaque size (F).
***p < 0.0001.intracellular phosphorylation events. We found that Kna selec-
tively inhibited Erk1/2 phosphorylation (Figure 3B) without any
effect on the phosphorylation of other MAP kinases (Figure 3B),
and without altering the phosphorylation of various transcription
factors, including p65, Stat1, or Stat3 (Figure S4). In addition,
inhibition of Erk1/2 phosphorylation reduced Il10 production
with no additive effect of Kna (Figure 3A), suggesting a selective
Erk-mediated effect of Kna on Il10 production. Interestingly,
Kna-mediated decrease of Il10 production was associated
with an increase of intracellular cyclic adenosine monophos-
phate (cAMP) (Figure 3C). Inversely, Ido1/ macrophages
stimulated with LPS and Ifn-g exhibited lower levels of intra-
cellular cAMP compared with Ido1+/+ cells (Figure 3D). Further-
more, inhibition of cAMP production using adenylate cyclase in-
hibitor (9-cyclopentyladenine monomethanesulfonate) markedly
decreased intracellular cAMP (Figure S5) and abolished the
inhibitory effect of Kna on Il10 production (Figure 3E), further
supporting a cAMP-mediated Kna effect. Kna may inhibit meth-
otrexate transport through the multidrug resistance protein 4
(Mrp4, also known as Abcc4 [Mutsaers et al., 2011]), a trans-
porter known to regulate intracellular cAMP levels (Van Aubel
et al., 2005; Wielinga et al., 2003). We therefore hypothesized
that Kna modulates Il10 production by antagonizing Mrp4. We
found that inhibition of Mrp1/4 with MK571 (Copsel et al.,
2011) increased intracellular cAMP (Figure S5) mimicked the ef-
fect of Kna on Il10 production, and prevented any additional Kna
effect on Il10 (Figure 3F). cAMP-dependent protein kinase (PKA)
inhibits serine/threonine-protein kinase (c-Raf), thereby reducing
P-Erk1/2 (Dumaz andMarais, 2005). As shown in Figure S5, inhi-
bition of c-Raf activity partially attenuated Kna inhibitory effect
on Il10 production, suggesting involvement of c-Raf in addition
to other pathways.464 Cell Metabolism 22, 460–471, September 1, 2015 ª2015 Elsevier Inc.Supplementation with Kna Limits
Il10 Production In Vivo and
Enhances Lesion Size
We then examined the effect of Kna on
Il10 production in vivo. Resupplementa-
tion of Ldlr/ Ido1/ mice with Kna
(Figure 3G) markedly suppressed Il10
expression in spleens (Figure 3H) with
no effect on Il12 or Il4 (data not shown).
Thus, increased production of Il10 in the
absence of Ido1 was in large part due to
reduced generation of Kna. Importantly,
reduced Il10 production after resupple-mentation with Kna was associated with a marked increase of
plaque size despite no alteration of plasma cholesterol levels
(Figures 4A–4C). Moreover, plasma Kna levels were strongly
correlated with plaque size and inversely correlated with Il10
expression (Figures 4D–4F).
Higher Kna Levels Are Associated with Human Unstable
Plaque Phenotype and Predict Adverse Cardiovascular
Outcome in Patients with Acute Myocardial Infarction
Previous studies suggested an intriguing positive relationship be-
tween Ido metabolites and cardiovascular events (Pedersen
et al., 2011, 2015). However, the relationship between Kna pro-
duction, plaque instability, and cardiovascular mortality has not
been explored. We detected high levels of Kna in unstable ather-
omatous plaques, whereas no detection or low levels of Knawere
found in stable fibrous plaques (Figure 5A). We therefore as-
sessed the relationship between circulating levels of Trp, Kyn,
and Kna and clinical characteristics of 981 patients at the admis-
sion for acutemyocardial infarction (MI), aswell as theoccurrence
of major clinical events, i.e., all-cause death and/or recurrent MI,
during 2 years of follow-up. High levels of Kna were more preva-
lent in females and were associated with older age, history of
hypertension, and chronic renal failure, and with a more severe
diseasepresentationas revealedbyahigherGRACEscore (Eagle
et al., 2004) at admission (Table S1). We found no correlation be-
tween Kna and levels of C-reactive protein (CRP), a systemic
marker of inflammation, suggesting independent pathophysio-
logical pathways. Interestingly, high levels of Kna were asso-
ciated with lower levels of Trp (r = 0.82, p < 0.0001; Figure 5B),
indicating a strong association between Trp consumption
and enhanced generation of Kna. In contrast, Kyn showed
only weak positive correlation with Trp levels (r = 0.07). Of the
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Figure 5. Higher Kna Levels Are Associated
with Unstable Human Plaque Phenotype
and Predicts Adverse Cardiovascular Out-
comes
(A) Kna levels are substantially higher in unstable/
atheromatous plaques (n = 10) in comparison to
stable/fibrous plaques (n = 10).
(B) Relationship between plasma levels of Trp and
Kna in 981 patients at the admission for acute MI.
(C and D) Kaplan-Meier curves displaying the
occurrence of death and recurrent MI during the
2 years of follow-up according to tertiles of Trp (C) or
Kna (D). HR indicates Hazard Ratio. p values are
fully adjusted. ***p < 0.0001.981 patients enrolled, 175 patients (17.8%) died or had a recur-
rent MI during the 2 years of follow-up. Patients with low levels
of Trp or high levels of Kna at the time of admissionwere at higher
risk of death or recurrent MI during follow-up. After adjustment,
Trp and Kna remained independent correlates of the risk of death
or MI (Figures 5C and 5D). The hazard risks of death or recurrent
MI with increasing tertiles of Trp were 0.76 (0.53–1.10) and 0.55
(0.35–0.83) compared to the lowest tertile (p = 0.019) (Figure 5C).
The corresponding hazard risks of death or recurrent MI with
increasing tertiles of Kna were 1.38 (0.89–2.14) and 1.74 (1.14–
2.66) compared to the lowest tertile (p = 0.038) (Figure 5D).
However, Kyn levels or Kyn to Trp ratio were not significantly
associated with clinical outcomes (HR = 0.71, 95% CI 0.44–
1.15; and HR = 0.93, 95% CI 0.65–1.33, respectively).
Inhibition of Il10 Breaks Immune Homeostasis of Ido1-
Deficient Animals, Leading to Severe Spontaneous
Colitis and Increased Susceptibility to Atherosclerosis
To directly address the physiological relevance of enhanced
Il10 production by Ido1-deficient immune cells, we generated
Ido1/Il10/ mice. Strikingly, Ido1/Il10/ mice exhibited a
high incidence of rectal prolapse first detectable at 6–8 weeks
of age, which led to rapid weight loss and death. Indeed, a defect
of weight gain was observed in Ido1/Il10/ mice starting
around 8 weeks of age, which was not the case for the single
Ido1/ or Il10/ mice (Figure 6A). Analysis of the prevalence
of prolapse in the colony showed that by 20 weeks 90% of
Ido1/Il10/ mice had developed rectal prolapse (Figure 6B).
This was significantly higher than the very small percentage of
Il10/ mice (less than 5%) with rectal prolapse maintained in
the same SPF room during the same time period (Figure 6B).
No rectal prolapse was detected in Ido1/ mice (Figure 6B).
Rectal prolapse was associated with a shortening of the colons
of Ido1/Il10/ mice compared to Ido1/ or Il10/ mice
(Figure 6C). Interestingly, ileum explants from Ido1/ mice
produced higher levels of Il10 than Ido1+/+, indicating a local
Ido1-mediated Il10 regulation (Figure 6D). Furthermore, Ido activ-Cell Metabolism 22, 460–471,ity was significantly higher in serum,MLNs,
and spleens of Il10/ mice compared to
Il10+/+mice (FigureS6), suggesting a recip-
rocal regulation between Ido1 and Il10. Of
note, the level of another major tolerogenic
factor Tgfb (Travis et al., 2007) did not show
any significant alteration neither systemi-cally (serum) nor locally (colon) in Ido1/ or Il10/ mice
compared to Il10+/+mice (Figure S6), suggesting selective cross-
regulation between Ido1 and Il10 pathways.
Analysis ofgastrointestinal tract at7–14weeksofageconfirmed
the presence of a spontaneous gastrointestinal tract inflammation
in Ido1/Il10/ mice with increasing severity from the proximal
small intestine to the distal colon (Figure 6E). Il10/ mice
exhibited a mild colon inflammation, which occurred at later
time points (12–14 weeks of age), whereas no inflammation was
observed in Ido1/ gastrointestinal tract (Figure 6E). Immunohis-
tochemistry showed a massive infiltration of CD3+ T cells and F4/
80+ macrophages in the colon lamina propria of Ido1/Il10/
mice in comparison to Ido1/ and Il10/ mice (Figures 6F and
6G). Ido1/Il10/ mice also exhibited signs of autoimmunity as
assessed by the increase of spleen and MLN weights (Figures
7A and 7B) and higher levels of plasma anti-ss and anti-ds DNA
antibodies in comparison to Ido1/ or Il10/ mice (Figure 7C).
Cytokine secretion from cells stimulated with anti-CD3 and anti-
CD28 antibodies indicated a striking increase of Il17A and Ifn-g
produced byMLN and spleen T cells of Ido1/Il10/ in compar-
ison with Il10/ mice, while these cytokines remained barely
detectable in T cells of Ido1/ animals compared to controls (Fig-
ures 7D and 7E). Accordingly, higher levels of plasma IgG2c were
detected in Ido1/Il10/ (Figure 7F), indicating exacerbation of
Th1/Th17 activation responses. Thus, the resistance of Ido1/
mice to colitis is due to the release of Ido1-dependent brake on
Il10production,which then feedbacks tomaintain immunehomeo-
stasis in the absence of Ido1. We then examined the impact of
Ido1 deficiency on atherosclerosis in the presence or absence of
Il10. Ido1/Il-10// Ldlr/ mice displayed significant reduc-
tion of plasma cholesterol levels compared with Ido-1/ /
Ldlr/ mice (Figure S7), most probably due to gastrointestinal
abnormalities. Interestingly, the increase of lesion size for a
given change in cholesterol level was much more pronounced in
Ido-1/Il-10/ / Ldlr/ compared with Ido-1// Ldlr/
mice (Figure S7), indicating enhanced susceptibility to
atherosclerosis.September 1, 2015 ª2015 Elsevier Inc. 465
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Figure 6. Double Deficiency of Ido1 and Il10
Leads to Severe Spontaneous Colitis
(A) Weight curves of Cont (n = 5–20 mice), Ido1/
(n = 10–26 mice), Il10/ (n = 4–30 mice), or
Ido1/Il10/ (n = 4–27 mice) mice from 3 to
17 weeks of age.
(B) Prevalence of rectal prolapse in Cont (n = 20),
Il10/ (n = 40), Ido1/ (n = 20), or Ido1/Il10/
(n = 35) mice. ***p < 0.0001.
(C) Representative picture and quantification of
colon length from Cont mice (n = 9), Il10/ mice
(n = 13), Ido1/ (n = 7), and Ido1/Il10/ (n = 13)
of 7–14 weeks of age. Mean values ± SEM. Colons
showed the absence of formed stool and thick-
ening of the intestinal wall in Ido1/Il10/ mice.
(D) Il10 is increased in supernatants of ileum
explants isolated from Ido1/ in comparison to
Ido1+/+ and incubated for 48 hr, *p < 0.05.
(E) H&E staining of representative cross-sections
of distal colons (magnification, 203) and histo-
pathological score using proximal/median/distal
small intestine, cecum, and proximal/median/
distal colon from Cont (n = 4), Il10/ (n = 9),
Ido1/ (n = 5), and Ido1/Il10/ (n = 10) mice.
(F and G) Representative pictures of F4/80 staining
(F) and CD3 staining (G) and quantification of in-
flammatory cell infiltration in proximal/median/
distal colons from the same mice. *p < 0.05, **p <
0.001, ***p < 0.0001. See also Figures S6 and S7.DISCUSSION
Ido1 is a major immunoregulatory enzyme (Mellor and Munn,
2004; Munn and Mellor, 2007; Pallotta et al., 2011). Paradoxi-
cally, however, Ido1 appears to be dispensable for the mainte-
nance of self-tolerance under basal conditions in the absence466 Cell Metabolism 22, 460–471, September 1, 2015 ª2015 Elsevier Inc.of additional susceptibility factors (Rav-
ishankar et al., 2012). This discrepancy
has been difficult to interpret and has
been attributed to the development of
‘‘compensatory’’ mechanisms, without
any hint into the existence or relevance
of such potential regulatory pathways.
Our results clearly show that Ido1 plays
a more complex role in the regulation of
the immune response, and significantly
represses the production of a major
anti-inflammatory cytokine, Il10. Loss of
Ido1-dependent inhibition of Il10 main-
tains immune tolerance in Ido1/ mice,
thereby providing a mechanistic explana-
tion to the paradox of preservation of im-
mune homeostasis in settings of reduced
Ido1 activity. Our data clearly show that
the Il10 phenotype of Ido1 deficiency
is unlikely to be due to a nonspecific
compensatory developmental process,
because (1) direct manipulation of Ido ac-
tivity abolishes the difference in Il10 pro-
duction between wild-type and Ido1/
cells, and (2) the phenotype is rescuedboth in vitro and in vivo by resupplementation with Kna, indi-
cating that it is directly linked to Ido1 activity. The finding that
Ido1 activity leads to inhibition of Il10 is intriguing but is sup-
ported by other recent indirect observations. For example,
pharmacologic inhibition or genetic deletion of Ido1 reduces
the inflammatory response to LPS in vivo as revealed by reduced
A B
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Figure 7. Double Deficiency of Ido1 and Il10
Is Associated with Exacerbation of Th1/
Th17 Pathways
(A) Representative pictures of spleens and MLNs.
(B) Spleen and MLN weights from Cont (n = 9),
Il10/ (n = 13), Ido1/ (n = 7), and Ido1/Il10/
mice (n = 13) of 7–14 weeks of age.
(C) Right and left panels show circulating levels of
ssDNA and dsDNA antibodies in the different
groups of mice.
(D and E) Ifn-g and Il17 in supernatants of isolated
CD4+ cells fromMLNs (D) or spleens (E) from Cont
(n = 6), Il10/ (n = 6), Ido1/ (n = 6), and
Ido1/Il10/ mice (n = 6). CD4+ cells were
stimulated with anti-CD3 and anti-CD28 during
48 hr.
(F) Serum levels of IgG1 and IgG2c in Cont (n = 8),
Il10/ (n = 5), Ido1/ (n = 6), and Ido1/Il10/
mice (n = 6). Mean values ± SEM are shown. *p <
0.05, **p < 0.001, ***p < 0.0001.Tnfa, Il6, and Il12, and increased Il10 (Jung et al., 2009). More-
over, Von Bubnoff and colleagues showed that human Ido1-pos-
itive DC populations produced significantly more Il1b and Il15
and less Il10 and Il6 than the Ido1-negative subset after CD40L
stimulation (Von Bubnoff et al., 2011), which supports our finding
of a role for Ido1 in restraining Il10 production.Cell Metabolism 22, 460–471, SThe identification of Kna as an inhibitor
of Il10 production also suggests that the
targeting of enzymes involved in its gen-
eration might be an interesting strategy
to modulate immune responses. In this
regard, it is interesting to note that a reg-
ulatory macrophage subset that pro-
duces high levels of Il10 also shows the
highest levels of kynureninase expression
(Rivollier et al., 2012), which may suggest
diversion of Kyn pathway fromKna gener-
ation, thereby releasing a brake on Il10
production.
This study unravels a previously
unsuspected signaling transduction
pathway for Kna. We show that Kna in-
hibits Erk1/2 phosphorylation through a
cAMP-dependent pathway to limit Il10
production. Kna directly increases intra-
cellular cAMP levels, which is nicely
mirrored by the significant reduction of
intracellular cAMP in Ido1/ cells, indi-
cating a physiologically relevant effect.
The use of the Mrp1/4 inhibitor M571
strongly suggests that Kna enhances
intracellular cAMP through blockade of
cAMP export by Mrp1/4. It should be
acknowledged that MK571 also inhibits
leukotriene D4 (Ltd4) receptor (Paru-
churi et al., 2008). However, a selective
antagonist of Ltd4 receptor (LY171883)
did not alter Kna-mediated effect onIl10 (data not shown), further supporting a selective effect of
Kna through Mrp1/4.
In atherosclerosis, Ido1 has been suggested to play a protec-
tive role due to its potential immunomodulatory effect (Cuffy
et al., 2007). However, no study had directly examined the role
of Ido1 deficiency in this setting. Daissormont et al. reported aeptember 1, 2015 ª2015 Elsevier Inc. 467
protective effect of pDCs in a model of atherosclerosis and pro-
posed that it might be related to Ido1 activity (Daissormont et al.,
2011). The authors did not directly test the effect of Ido1 inhibi-
tion on atherosclerosis, and more recent data indicate a
proatherogenic role of pDCs (Do¨ring et al., 2012; Macritchie
et al., 2012; Sage et al., 2014). In one study (Nakajima et al.,
2011), administration of 1-MT to Ldlr/mice did not significantly
alter lesion formation. However in that study, 1-MT did not alter
Kyn levels. Zhang et al. examined the effect of supraphysiologi-
cal levels of 3-hydroxyanthranilic acid (3-HAA), a Kynmetabolite,
on atherogenesis in a mouse model. They showed reduced
disease development associated with a limited inflammatory
response (Zhang et al., 2012). However, those protective effects
weremost likely due to the profound reduction of plasma choles-
terol and triglycerides levels (50% and 75% reduction, respec-
tively) in 3-HAA-treated animals, rather than to a direct immuno-
modulatory role of 3-HAA. The same group recently reported
increased atherogenesis in Apoe–/– mice after treatment with
DL-1MT (Polyzos et al., 2015). However, circulating Ido activity
was not significantly reduced in DL-1MT-treated animals.
Moreover, the proatherogenic effect could be due to the signifi-
cant increase of circulating total cholesterol and the significant
decrease of HDL-cholesterol levels observed after DL-1MT
administration (Polyzos et al., 2015). Thus, although interesting,
previous work using DL-1MT and 3-HAA cannot be used to
inform on the direct role of Ido1 in atherogenesis. In the present
study, we found that L-1MTmarkedly reduced Ido activity in vivo
(as much as the complete deletion of Ido1) but also displayed
substantial off-target effects, as revealed by the 3-fold increase
of Il-12 production even in the absence of Ido1. Given the well-
described proatherogenic effects of Il-12, this off-target proin-
flammatory effect of L-1MT may have masked the potential
antiatherogenic role of reduced Ido1 activity. Together, our
data as well as previous studies (Agaugue´ et al., 2006; Lo¨b
et al., 2009a) clearly indicate that 1-MT may modulate immune
responses independently of Ido1.
Ido1 isexpressed inhumanatherosclerosis,where it colocalizes
with macrophages (Niinisalo et al., 2010). In translational studies
oncardiovascular biomarkers, Kyn:Trp ratiowasusedasamarker
of Ido1 activity and has been shown to be associated with some
cardiovascular risk factors (Niinisalo et al., 2008; Pertovaara
et al., 2007) and worse outcome in stable CAD patients (Pedersen
et al., 2011; Pedersen et al., 2015). However, results interpretation
was confounded by the fact that Ido1, as well as downstreamKyn
and Kyn metabolites, were considered atheroprotective. Our re-
sults extend the previous findings and point to a specific Ido1
metabolite,Kna, asa linkbetweenelevated Ido1activity and insta-
bility of atherosclerotic lesions. Moreover, we show that plasma
Kna levels significantly predict death and/or recurrent MI after an
index cardiovascular event. In this regard, it is important to note
that levels of Kna, but not Kyn, showed a very strong negative cor-
relationwith Trp levels, suggesting that the final generation of Kna,
rather than Kyn, may be a better (patho)physiological indicator of
Trp metabolism in CAD patients.
Ido1 expression and activity (including Kna levels) are elevated
in patients with inflammatory bowel disease and positively corre-
late with inflammation-induced colon tumorigenesis (Ciorba,
2013). However, the direct role of Ido1 in intestinal inflammation
and colitis is still unclear and varies according to the inducing468 Cell Metabolism 22, 460–471, September 1, 2015 ª2015 Elsevieagent (chemicals or gut microbiota/pathogens) (Takamatsu
et al., 2013). Consistently, however, Ido1 deficiency per se
does not promote spontaneous intestinal inflammation. In this
report, we found that Ido1/ mice maintain intestinal immune
homeostasis through upregulation of Il10. Abrogation of Il10 in
Ido1/ animals led to spontaneous development of a fulminant
Th1/Th17-associated colitis that was much more severe than
the mild form of the disease induced by a single Il10 deficiency
under C57Bl/6 background (Berg et al., 1996), strongly high-
lighting the interplay between Ido1 and Il10 pathways in the
fine-tuning of immune responses and the maintenance of im-
mune homeostasis.
In summary, we have identified a previously unsuspected role
for Ido1 activity in the control of Il10 production, in part through
the generation of Kna. The results provide a mechanistic expla-
nation for the preservation of immune homeostasis in Ido1/
animals. We expect these findings to shed new light on the path-
ophysiology of disease states where Trp metabolism is shown to
play a significant role.
EXPERIMENTAL PROCEDURES
Animals
C57BL/6 Ido1/, Il10/, and Ldlr–/– mice were from the Jackson Laboratory.
Ldlr–/–Ido1–/– and Ido1/Il10/ mice were generated by crossing, respec-
tively, Ldlr/ to Ido1/ and Ido1/ to Il10/ mice. Seven- to ten-week-
old Ldlr–/– and Ldlr–/–Ido1–/–male mice were subjected to proatherogenic diet
containing 15% fat, 1.25% cholesterol, and 0% cholate for 8 weeks. We
also subjected 20-week-old Ldlr–/– female tomedullar aplasia by 9.5 gray lethal
total body irradiation.We repopulated themice with an intravenous injection of
bone marrow cells isolated from femurs and tibias of age- and sex-matched
C57Bl/6Jmice (Cont), Ido1–/–. After 4 weeks of recovery, mice were fed a proa-
therogenic diet for 6 weeks. In some experiments, Ldlr–/–Ido1–/–mice received
continuous infusion with control vehicle (DMSO) or Kna (10 mg/kg/day) using
ALZET osmotic pumps (Charles River Laboratories) during 7 weeks of fat diet.
Some Ldlr–/– mice were treated with L-1MT, which is known to inhibit Ido1
activity (pump infusion 10 mg/kg/day during 7 weeks of FAT diet). All mice
used in these experiments were bred and housed in a specific pathogen-
free (SPF) barrier facility. Experiments were conducted according to the
French veterinary guidelines and those formulated by the European commu-
nity for experimental animal use (L358-86/609EEC).
Extent of Atherosclerotic Lesions
Mice were anesthetized with isoflurane before sacrifice. Plasma cholesterol
wasmeasured using a commercial cholesterol kit (Sigma). The heart and aorta,
including the brachiocephalic artery, were taken off and fixed in 4% parafor-
maldehyde for 2 hr. Lipids were detected using oil red O coloration.
Determination of Antibody Level
IgG antibodies to single-stranded (ss) DNA and double-stranded (ds) DNA
were determined and quantified in mice serums by using commercially avail-
able kits (Alpha Diagnostic International). Measurements of serum IgG1 and
IgG2c have been performed using ELISA kits (eBioscience).
Human Carotid Plaques
The processing and examination of the dissected atherosclerotic plaques has
been described previously (Taleb et al., 2009).
HPLC Quantifications
Ido1 metabolites were quantified from the plasma of mice according to previ-
ously published methods (Laich et al., 2002).
Cell Recovery and Differentiation
Cells were cultured in RPMI 1640 supplemented with Glutamax, 10% FCS,
0.02 mM 2b-mercaptoethanol, and antibiotics. Splenocytes from Ldlr–/– andr Inc.
Ldlr–/–Ido1–/– were stimulated with LPS (1 mg/ml) and Ifn-g (100 U/ml) (Sigma)
for 48 hr, and then supernatants were subjected to cytokine measurements.
Resident peritoneal cells were harvested from Ldlr–/– and Ldlr–/–Ido1–/– by
washing the peritoneumwith PBS. Then cells were resuspended in lysis buffer
for western blot. Macrophages were prepared from mouse bone marrow.
Briefly, tibias and femurs of C57Bl/6 mice were dissected and their marrow
flushed out. Cells were grown for 7 days at 37C in RPMI 1640 medium,
20% FCS, and 20% macrophage-colony-stimulating factor (M-CSF)-rich
L929-conditionedmedium. Then, differentiatedmacrophages were stimulated
with LPS (1 mg/ml) and Ifn-g (100 U/ml) for 24 or 3 hr in the absence or in the
presence of Kna or Kyn or quinolinic acid (Quina) (1 mM). Phospho-Erk inhib-
itor (PD98059, Sigma) 105 M, inhibitor of Mrp1/4 (MK 571, Sigma) 10 mM,
inhibitor of Ido1 (L-1MT, Sigma) 200 nM, inhibitor of adenylate cyclase (9-cy-
clopentyladenine monomethanesulfonate, Sigma) 10 mM, inhibitor of c-Raf
(475958, Calbiochem) 100 nM, antagonist of LTD4 receptor (LY 171883)
1 mM, or DPI (Sigma) 1 mM was used in some conditions. Additionally, CpG
type B (500 ng/ml) and Poly:IC 200 ng/ml (Invivogen) were used in some
experiments.
FAST-MI Study Population
The population and methods of the French registry of Acute ST-elevation and
non-ST-elevation Myocardial Infarction (FAST-MI) have been described in
detail in previous publications (Cambou et al., 2007; Simon et al., 2009). The
study was reviewed by the Committee for the Protection of Human Subjects
in Biomedical Research of Saint Antoine University Hospital and the data file
was declared to the Commission Nationale Informatique et Liberte´.
Histologic Scoring of Gastrointestinal Inflammation
Sections of the duodenum, jejunum, ileum, cecum, proximal colon, medial co-
lon, and distal colon were fixed in 10% neutral buffered formalin and stained
with hematoxylin and eosin for histologic scoring. Each gastrointestinal loca-
tion was scored independently as previously described (Berg et al., 1996).
Statistical Analysis
Values are expressed as means ± SEM. Differences between values were
examined using Student’s t test. MannWhitney is applied in the animal studies.
Values were considered significant at p% 0.05. All statistical tests were two-
sided and performed using SAS software version 9.1.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, and Supple-
mental Experimental Procedures and can be found with this article at http://
dx.doi.org/10.1016/j.cmet.2015.07.004.
AUTHOR CONTRIBUTIONS
S.M. was involved in experimental design, conducted most experiments, and
analyzed data. P.P. conducted flow cytometry and biochemical experiments
and analyzed data. T.S. and N.D designed the human studies and analyzed
corresponding data. S.M., V.K., M.R., and L.L. conducted the atherosclerosis
experiments. M.D. and B.E. were involved in animal experiments. J.-L.P. con-
ducted biochemical measurements on animals. S.K. analyzed human data.
H.d.R. provided human material for the study. P.B. conducted histological
analysis. J.-M.L. and J.C. measured all biochemical parameters in human
samples. B.L. and H.S. participated in the colitis study. A.T. was involved in
study design and data interpretation. S.T. was involved in experimental design,
analyzed and interpreted data, and wrote part of the manuscript. Z.M.
conceived the project, provided funding, interpreted the data, and wrote
part of the manuscript.
ACKNOWLEDGMENTS
This work was supported by Inserm, FP7 TOLERAGE (Z.M.); British Heart
Foundation and European Research Council (Z.M.); and De´partement Hospi-
talo-Universitaire Pathologies Arte´rielles Rares et Communes (S.T. and A.T.).
P.P., Y.H., and M.R. were the recipients of fellowships from CODDIM,
Ile-de-France, Paris. We thank the physicians who cared for the patients atCell Methe participating institutions, the International Clinical Trials Association Con-
tract Research Organization (Fontaine-le`s-Dijon, France); Elodie Drouet and
the Clinical Research Assistant team of Unite´ de Recherche Clinique de l’Est
Parisien (Assistance Publique–Hoˆpitaux de Paris and UPMC Paris 06); and
Benoıˆt Pace, Vincent Bataille, and Genevie`ve Mulak (French Society of Cardi-
ology) for their assistance in designing the electronic case record form and
data management during the follow-up period.
Received: March 6, 2015
Revised: May 6, 2015
Accepted: July 1, 2015
Published: July 30, 2015
REFERENCES
Agaugue´, S., Perrin-Cocon, L., Coutant, F., Andre´, P., and Lotteau, V. (2006).
1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells inde-
pendently of IDO activity. J. Immunol. 177, 2061–2071.
Berg, D.J., Davidson, N., Ku¨hn, R., Mu¨ller, W., Menon, S., Holland, G.,
Thompson-Snipes, L., Leach, M.W., and Rennick, D. (1996). Enterocolitis
and colon cancer in interleukin-10-deficient mice are associated with aberrant
cytokine production and CD4(+) TH1-like responses. J. Clin. Invest. 98, 1010–
1020.
Cambou, J.P., Simon, T., Mulak, G., Bataille, V., and Danchin, N. (2007). The
French registry of Acute ST elevation or non-ST-elevation Myocardial
Infarction (FAST-MI): study design and baseline characteristics. Arch. Mal.
Coeur Vaiss. 100, 524–534.
Ciorba, M.A. (2013). Indoleamine 2,3 dioxygenase in intestinal disease. Curr.
Opin. Gastroenterol. 29, 146–152.
Copsel, S., Garcia, C., Diez, F., Vermeulem, M., Baldi, A., Bianciotti, L.G.,
Russel, F.G., Shayo, C., and Davio, C. (2011). Multidrug resistance protein 4
(MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia
cell proliferation and differentiation. J. Biol. Chem. 286, 6979–6988.
Cuffy, M.C., Silverio, A.M., Qin, L., Wang, Y., Eid, R., Brandacher, G., Lakkis,
F.G., Fuchs, D., Pober, J.S., and Tellides, G. (2007). Induction of indoleamine
2,3-dioxygenase in vascular smooth muscle cells by interferon-gamma
contributes to medial immunoprivilege. J. Immunol. 179, 5246–5254.
Daissormont, I.T., Christ, A., Temmerman, L., SampedroMillares, S., Seijkens,
T., Manca, M., Rousch, M., Poggi, M., Boon, L., van der Loos, C., et al. (2011).
Plasmacytoid dendritic cells protect against atherosclerosis by tuning T-cell
proliferation and activity. Circ. Res. 109, 1387–1395.
Davenport, P., and Tipping, P.G. (2003). The role of interleukin-4 and inter-
leukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient
mice. Am. J. Pathol. 163, 1117–1125.
Do¨ring, Y., Manthey, H.D., Drechsler, M., Lievens, D., Megens, R.T.,
Soehnlein, O., Busch, M., Manca, M., Koenen, R.R., Pelisek, J., et al. (2012).
Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells
to promote atherosclerosis. Circulation 125, 1673–1683.
Dumaz, N., and Marais, R. (2005). Integrating signals between cAMP and the
RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of
the Gesellschaft fu¨r Biochemie und Molekularbiologie Lecture delivered on 5
July 2003 at the Special FEBS Meeting in Brussels. FEBS J. 272, 3491–3504.
Eagle, K.A., Lim, M.J., Dabbous, O.H., Pieper, K.S., Goldberg, R.J., Van de
Werf, F., Goodman, S.G., Granger, C.B., Steg, P.G., Gore, J.M., et al.
(2004). A validated prediction model for all forms of acute coronary syndrome:
estimating the risk of 6-month postdischarge death in an international registry.
J. Am. Med. Assoc. 291, 2727–2733.
Gilliet, M., Boonstra, A., Paturel, C., Antonenko, S., Xu, X.L., Trinchieri, G.,
O’Garra, A., and Liu, Y.J. (2002). The development of murine plasmacytoid
dendritic cell precursors is differentially regulated by FLT3-ligand and granulo-
cyte/macrophage colony-stimulating factor. J. Exp. Med. 195, 953–958.
Hauer, A.D., Uyttenhove, C., de Vos, P., Stroobant, V., Renauld, J.C., van
Berkel, T.J., van Snick, J., and Kuiper, J. (2005). Blockade of interleukin-12
function by protein vaccination attenuates atherosclerosis. Circulation 112,
1054–1062.tabolism 22, 460–471, September 1, 2015 ª2015 Elsevier Inc. 469
Jung, I.D., Lee,M.G., Chang, J.H., Lee, J.S., Jeong, Y.I., Lee, C.M., Park,W.S.,
Han, J., Seo, S.K., Lee, S.Y., and Park, Y.M. (2009). Blockade of indoleamine
2,3-dioxygenase protects mice against lipopolysaccharide-induced endo-
toxin shock. J. Immunol. 182, 3146–3154.
Laich, A., Neurauter, G., Widner, B., and Fuchs, D. (2002). More rapid method
for simultaneous measurement of tryptophan and kynurenine by HPLC. Clin.
Chem. 48, 579–581.
Lo¨b, S., Ko¨nigsrainer, A., Rammensee, H.G., Opelz, G., and Terness, P.
(2009a). Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can
we see the wood for the trees? Nat. Rev. Cancer 9, 445–452.
Lo¨b, S., Ko¨nigsrainer, A., Zieker, D., Bru¨cher, B.L., Rammensee, H.G., Opelz,
G., and Terness, P. (2009b). IDO1 and IDO2 are expressed in human tumors:
levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism.
Cancer Immunol. Immunother. 58, 153–157.
Macritchie, N., Grassia, G., Sabir, S.R., Maddaluno, M., Welsh, P., Sattar, N.,
Ialenti, A., Kurowska-Stolarska, M., McInnes, I.B., Brewer, J.M., et al. (2012).
Plasmacytoid dendritic cells play a key role in promoting atherosclerosis in
apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 32, 2569–
2579.
Mellor, A.L., and Munn, D.H. (2004). IDO expression by dendritic cells: toler-
ance and tryptophan catabolism. Nat. Rev. Immunol. 4, 762–774.
Mellor, A.L., Chandler, P., Baban, B., Hansen, A.M., Marshall, B., Pihkala, J.,
Waldmann, H., Cobbold, S., Adams, E., and Munn, D.H. (2004). Specific
subsets of murine dendritic cells acquire potent T cell regulatory functions
following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int.
Immunol. 16, 1391–1401.
Moore, K.W., de Waal Malefyt, R., Coffman, R.L., and O’Garra, A. (2001).
Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19,
683–765.
Munn, D.H., and Mellor, A.L. (2007). Indoleamine 2,3-dioxygenase and tumor-
induced tolerance. J. Clin. Invest. 117, 1147–1154.
Munn, D.H., Zhou, M., Attwood, J.T., Bondarev, I., Conway, S.J., Marshall, B.,
Brown, C., and Mellor, A.L. (1998). Prevention of allogeneic fetal rejection by
tryptophan catabolism. Science 281, 1191–1193.
Munn, D.H., Sharma, M.D., Baban, B., Harding, H.P., Zhang, Y., Ron, D., and
Mellor, A.L. (2005). GCN2 kinase in T cells mediates proliferative arrest and
anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22,
633–642.
Mutsaers, H.A., van den Heuvel, L.P., Ringens, L.H., Dankers, A.C., Russel,
F.G., Wetzels, J.F., Hoenderop, J.G., and Masereeuw, R. (2011). Uremic
toxins inhibit transport by breast cancer resistance protein and multidrug
resistance protein 4 at clinically relevant concentrations. PLoS ONE 6,
e18438.
Nakajima, K., Yamashita, T., Kita, T., Takeda, M., Sasaki, N., Kasahara, K.,
Shinohara, M., Rikitake, Y., Ishida, T., Yokoyama, M., and Hirata, K. (2011).
Orally administered eicosapentaenoic acid induces rapid regression of athero-
sclerosis via modulating the phenotype of dendritic cells in LDL receptor-defi-
cient mice. Arterioscler. Thromb. Vasc. Biol. 31, 1963–1972.
Niinisalo, P., Raitala, A., Pertovaara, M., Oja, S.S., Lehtima¨ki, T., Ka¨ho¨nen, M.,
Reunanen, A., Jula, A., Moilanen, L., Kesa¨niemi, Y.A., et al. (2008). Indoleamine
2,3-dioxygenase activity associates with cardiovascular risk factors: the
Health 2000 study. Scand. J. Clin. Lab. Invest. 68, 767–770.
Niinisalo, P., Oksala, N., Levula, M., Pelto-Huikko, M., Ja¨rvinen, O., Salenius,
J.P., Kyto¨ma¨ki, L., Soini, J.T., Ka¨ho¨nen, M., Laaksonen, R., et al. (2010).
Activation of indoleamine 2,3-dioxygenase-induced tryptophan degradation
in advanced atherosclerotic plaques: Tampere vascular study. Ann. Med.
42, 55–63.
Opitz, C.A., Litzenburger, U.M., Sahm, F., Ott, M., Tritschler, I., Trump, S.,
Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011). An endog-
enous tumour-promoting ligand of the human aryl hydrocarbon receptor.
Nature 478, 197–203.
Pallotta, M.T., Orabona, C., Volpi, C., Vacca, C., Belladonna, M.L., Bianchi, R.,
Servillo, G., Brunacci, C., Calvitti, M., Bicciato, S., et al. (2011). Indoleamine470 Cell Metabolism 22, 460–471, September 1, 2015 ª2015 Elsevie2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells.
Nat. Immunol. 12, 870–878.
Paruchuri, S., Jiang, Y., Feng, C., Francis, S.A., Plutzky, J., and Boyce, J.A.
(2008). Leukotriene E4 activates peroxisome proliferator-activated receptor
gamma and induces prostaglandin D2 generation by human mast cells.
J. Biol. Chem. 283, 16477–16487.
Pedersen, E.R., Midttun, Ø., Ueland, P.M., Schartum-Hansen, H., Seifert, R.,
Igland, J., Nordrehaug, J.E., Ebbing, M., Svingen, G., Bleie, Ø., et al. (2011).
Systemic markers of interferon-g-mediated immune activation and long-
term prognosis in patients with stable coronary artery disease. Arterioscler.
Thromb. Vasc. Biol. 31, 698–704.
Pedersen, E.R., Tuseth, N., Eussen, S.J., Ueland, P.M., Strand, E., Svingen,
G.F., Midttun, O., Meyer, K., Mellgren, G., Ulvik, A., et al. (2015).
Associations of plasma kynurenines with risk of acute myocardial infarction
in patients with stable angina pectoris. Arterioscler. Thromb. Vasc. Biol. 35,
455–462.
Pertovaara, M., Raitala, A., Juonala, M., Lehtima¨ki, T., Huhtala, H., Oja, S.S.,
Jokinen, E., Viikari, J.S., Raitakari, O.T., and Hurme, M. (2007). Indoleamine
2,3-dioxygenase enzyme activity correlates with risk factors for atheroscle-
rosis: the Cardiovascular Risk in Young Finns Study. Clin. Exp. Immunol.
148, 106–111.
Platten, M., Ho, P.P., Youssef, S., Fontoura, P., Garren, H., Hur, E.M., Gupta,
R., Lee, L.Y., Kidd, B.A., Robinson, W.H., et al. (2005). Treatment of autoim-
mune neuroinflammation with a synthetic tryptophan metabolite. Science
310, 850–855.
Polyzos, K.A., Ovchinnikova, O., Berg, M., Baumgartner, R., Agardh, H.,
Pirault, J., Gistera˚, A., Assinger, A., Laguna-Fernandez, A., Ba¨ck, M., et al.
(2015). Inhibition of indoleamine 2,3-dioxygenase promotes vascular inflam-
mation and increases atherosclerosis in Apoe-/- mice. Cardiovasc. Res.
106, 295–302.
Ravishankar, B., Liu, H., Shinde, R., Chandler, P., Baban, B., Tanaka, M.,
Munn, D.H., Mellor, A.L., Karlsson, M.C., and McGaha, T.L. (2012).
Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase.
Proc. Natl. Acad. Sci. USA 109, 3909–3914.
Rivollier, A., He, J., Kole, A., Valatas, V., and Kelsall, B.L. (2012). Inflammation
switches the differentiation program of Ly6Chi monocytes from antiinflamma-
tory macrophages to inflammatory dendritic cells in the colon. J. Exp. Med.
209, 139–155.
Romani, L., Fallarino, F., De Luca, A., Montagnoli, C., D’Angelo, C., Zelante, T.,
Vacca, C., Bistoni, F., Fioretti, M.C., Grohmann, U., et al. (2008). Defective
tryptophan catabolism underlies inflammation in mouse chronic granuloma-
tous disease. Nature 451, 211–215.
Saraiva, M., and O’Garra, A. (2010). The regulation of IL-10 production by
immune cells. Nat. Rev. Immunol. 10, 170–181.
Sage, A.P., Murphy, D., Maffia, P., Masters, L.M., Sabir, S.R., Baker, L.L.,
Cambrook, H., Finigan, A.J., Ait-Oufella, H., Grassia, G., et al. (2014). MHC
class II-restricted antigen presentation by plasmacytoid dendritic cells drives
proatherogenic T cell immunity. Circulation 130, 1363–1373.
Segal, B.M., Dwyer, B.K., and Shevach, E.M. (1998). An interleukin (IL)-10/IL-
12 immunoregulatory circuit controls susceptibility to autoimmune disease.
J. Exp. Med. 187, 537–546.
Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Me´neveau,
N., Steg, P.G., Ferrie`res, J., Danchin, N., and Becquemont, L.; French Registry
of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI)
Investigators (2009). Genetic determinants of response to clopidogrel and car-
diovascular events. N. Engl. J. Med. 360, 363–375.
Takamatsu, M., Hirata, A., Ohtaki, H., Hoshi, M., Hatano, Y., Tomita, H., Kuno,
T., Saito, K., and Hara, A. (2013). IDO1 plays an immunosuppressive role in
2,4,6-trinitrobenzene sulfate-induced colitis in mice. J. Immunol. 191, 3057–
3064.
Taleb, S., Romain, M., Ramkhelawon, B., Uyttenhive, C., Pasterkamp, G.,
Herbin, O., Esposito, B., Perez, N., Yasukawa, H., Van Snick, J., et al.
(2009). Loss of SOCS3 expression in T cells reveals a regulatory role for inter-
lukin-17 in atherosclerosis. J. Exp. Med. 206, 2067–2077.r Inc.
Tedgui, A., and Mallat, Z. (2006). Cytokines in atherosclerosis: pathogenic and
regulatory pathways. Physiol. Rev. 86, 515–581.
Terness, P., Bauer, T.M., Ro¨se, L., Dufter, C., Watzlik, A., Simon, H., and
Opelz, G. (2002). Inhibition of allogeneic T cell proliferation by indoleamine
2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryp-
tophan metabolites. J. Exp. Med. 196, 447–457.
Travis, M.A., Reizis, B., Melton, A.C., Masteller, E., Tang, Q., Proctor, J.M.,
Wang, Y., Bernstein, X., Huang, X., Reichardt, L.F., et al. (2007). Loss of integ-
rin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice.
Nature 449, 361–365.
Van Aubel, R.A., Smeets, P.H., van den Heuvel, J.J., and Russel, F.G. (2005).
Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the
purine end metabolite urate with multiple allosteric substrate binding sites.
Am. J. Physiol. Renal Physiol. 288, F327–F333.
Von Bubnoff, D., Scheler, M., Wilms, H., Fimmers, R., and Bieber, T.
(2011). Identification of IDO-positive and IDO-negative human dendriticCell Mecells after activation by various proinflammatory stimuli. J. Immunol. 186,
6701–6709.
Wielinga, P.R., van der Heijden, I., Reid, G., Beijnen, J.H., Wijnholds, J., and
Borst, P. (2003). Characterization of the MRP4- and MRP5-mediated
transport of cyclic nucleotides from intact cells. J. Biol. Chem. 278,
17664–17671.
Yoshida, R., Imanishi, J., Oku, T., Kishida, T., and Hayaishi, O. (1981).
Induction of pulmonary indoleamine 2,3-dioxygenase by interferon. Proc.
Natl. Acad. Sci. USA 78, 129–132.
Zelante, T., Fallarino, F., Bistoni, F., Puccetti, P., and Romani, L. (2009).
Indoleamine 2,3-dioxygenase in infection: the paradox of an evasive strategy
that benefits the host. Microbes Infect. 11, 133–141.
Zhang, L., Ovchinnikova, O., Jo¨nsson, A., Lundberg, A.M., Berg, M., Hansson,
G.K., and Ketelhuth, D.F. (2012). The tryptophan metabolite 3-hydroxyanthra-
nilic acid lowers plasma lipids and decreases atherosclerosis in hypercholes-
terolaemic mice. Eur. Heart J. 33, 2025–2034.tabolism 22, 460–471, September 1, 2015 ª2015 Elsevier Inc. 471
